The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign